Summary
This review examines iPSC-based methods for generating retinal cell types such as photoreceptors and retinal ganglion cells, providing a platform for studying retinal degeneration diseases like glaucoma and AMD. While primarily a research tool, advances in retinal organoid development could eventually inform therapeutic strategies for vision-threatening conditions relevant to lighting-sensitive populations.
Key Findings
- iPSC-derived retinal organoids can recapitulate key stages of human retinogenesis and serve as in vitro models for diseases such as retinitis pigmentosa, glaucoma, and age-related macular degeneration.
- Current cell replacement therapies derived from iPSCs remain insufficient to cure or reverse retinal degenerative conditions, highlighting the ongoing need for improved differentiation protocols and functional validation of retinal neurons.
Categories
Eye Health & Vision: Covers retinal degenerative diseases including glaucoma, retinitis pigmentosa, and AMD, and stem cell-based approaches to model and treat them.
Author(s)
NK Wong, SP Yip, CL Huang
Publication Year
2023
Related Publications
Eye Health & Vision
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa
- Melanopsin and rod–cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humans
- Characteristic patterns of dendritic remodeling in early-stage glaucoma: evidence from genetically identified retinal ganglion cell types
- Intrinsically photosensitive melanopsin retinal ganglion cell contributions to the pupillary light reflex and circadian rhythm